Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

MM.1S multiple myeloma cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (9) Arenavirus (1) Autophagy (1) Bcl-2 Family (1) ByeTAC (1) c-Myc (1) Casein Kinase (2) Caspase (1) CD38 (1) DNA Alkylator/Crosslinker (3) DNA/RNA Synthesis (1) Epigenetic Reader Domain (2) HDAC (5) Histone Demethylase (4) HSP (1) IGF-1R (1) Insulin Receptor (1) MMP (1) Molecular Glues (4) Monoamine Oxidase (1) Phosphodiesterase (PDE) (2) PI4K (1) PROTACs (3) Proteasome (2) Reference Standards (1) SOD (1)
By Research Areas:	Cancer (26) Cardiovascular Disease (1) Infection (1) Neurological Disease (1)

By Targets:

Akt (1)

Apoptosis (9)

Arenavirus (1)

Autophagy (1)

Bcl-2 Family (1)

ByeTAC (1)

c-Myc (1)

Casein Kinase (2)

Caspase (1)

CD38 (1)

DNA Alkylator/Crosslinker (3)

DNA/RNA Synthesis (1)

Epigenetic Reader Domain (2)

HDAC (5)

Histone Demethylase (4)

HSP (1)

IGF-1R (1)

Insulin Receptor (1)

MMP (1)

Molecular Glues (4)

Monoamine Oxidase (1)

Phosphodiesterase (PDE) (2)

PI4K (1)

PROTACs (3)

Proteasome (2)

Reference Standards (1)

SOD (1)

By Research Areas:

Cancer (26)

Cardiovascular Disease (1)

Infection (1)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) TREM receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13560

AVN-944 5 Publications Verification VX-944	Arenavirus DNA/RNA Synthesis Apoptosis Caspase Bcl-2 Family	Infection Cancer
AVN-944 (VX-944) is an orally active, potent, selective, noncompetitive and specific inhibitor of IMPDH (inosine monophosphate dehydrogenase). AVN-944 is an essential rate-limiting enzyme in de novo guanine nucleotide synthesis. AVN-944 is also an inhibitor of arenavirus RNA synthesis, and blocks arenavirus infection. AVN-944 has broad anti-cancer activities, and can be used for multiple myeloma (MM) and acute myeloid leukemia (AML) research .

HY-115445

LCS-1 3 Publications Verification	Apoptosis SOD	Cancer
LCS-1 is a superoxide dismutase 1 (SOD1) inhibitor. LCS-1 inhibits SOD1 activity with an IC₅₀ value of 1.07 μM. LCS-1 induces the early- and late-stage apoptosis of multiple myeloma (MM.1S) cells .

HY-145322

TMX-4116	Casein Kinase Molecular Glues	Cancer
TMX-4116 is a casein kinase 1α (CK1α) degrader. TMX-4116 shows the degradation preference for CK1α with DC₅₀s less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4116 can be used for the research of multiple myeloma .

HY-145667

Biotinylated-JQ1 1 Publications Verification Biotin-JQ1	Epigenetic Reader Domain	Cancer
Biotinylated-JQ1 (Biotin-JQ1) is a biotinylated derivative of JQ1 with high affinity for the bromodomain of BRD4. Biotinylated-JQ1 inhibits MM1.S multiple myeloma cells proliferation with the EC₅₀ of 0.4 μM .

HY-102047B

KDOAM-25 citrate Maximum Cited Publications 9 Publications Verification	Histone Demethylase	Cancer
KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 citrate increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells .

HY-145321

TMX-4100	Phosphodiesterase (PDE) Molecular Glues	Cancer
TMX-4100 is a selective phosphodiesterase 6D (PDE6D) degrader. TMX-4100 shows a high degradation preference for PDE6D with the DC₅₀ values less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4100 can be used for the research of multiple myeloma .

HY-105019A

Melflufen hydrochloride 1 Publications Verification Melphalan flufenamide hydrochloride	DNA Alkylator/Crosslinker Apoptosis	Cancer
Melflufen (Melphalan flufenamide) hydrochloride, a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen hydrochloride shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen hydrochloride induces irreversible DNA damage and cytotoxicity in MM cells .

HY-144763

XPO1-IN-1	Apoptosis	Cancer
XPO1-IN-1 (compound D4) is an orally active and potent XPO1 inhibitor, with an IC₅₀ of 24 nM in MM.1S cell. XPO1-IN-1 can efficiently induce cell apoptosis and cell cycle arrest. XPO1-IN-1 displays favorable metabolic stability and pharmacokinetic properties. XPO1-IN-1 can be used for multiple myeloma (MM) research .

HY-145320

TMX-4113	Molecular Glues Phosphodiesterase (PDE) Casein Kinase	Cancer
TMX-4113 is a degrader of phosphodiesterase 6D (PDE6D) and casein kinase 1α (CK1α). TMX-4113 can be used for the research of cancer .

HY-164099

LSD1/HDAC6-IN-2	HDAC Monoamine Oxidase Histone Demethylase	Cancer
LSD1/HDAC6-IN-2 (JBI-802) is an orally active LSD1/HDAC6/MAO-A inhibitor, with IC₅₀ values of 5 nM, 11 nM, and 5 nM, respectively. LSD1/HDAC6-IN-2 can inhibit the growth of multiple myeloma cells MM.1S, MM.1R, and RPMI-8226. LSD1/HDAC6-IN-2 can be used for research on diseases such as acute myeloid leukemia and lymphoma .

HY-105019

Melflufen 1 Publications Verification Melphalan flufenamide	DNA Alkylator/Crosslinker Apoptosis	Cancer
Melflufen (Melphalan flufenamide), a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen induces irreversible DNA damage and cytotoxicity in MM cells .

HY-157216

HDAC1 Degrader-1	HDAC	Cancer
HDAC1 Degrader-1 (compound 1a) is an HDAC1 degrader with anticancer activity. HDAC1 Degrader-1 significantly reduces HDAC1 levels in MM.1S multiple myeloma cells .

HY-102047

KDOAM-25	Histone Demethylase	Cancer
KDOAM-25 is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells .

HY-177725

MG degrader 2	Molecular Glues PI4K	Cancer
MG degrader 2 (Compound CM-2) is a CRBN-dependent molecular glue degrader. MG degrader 2 induces ZFP91, FIZ1 and PI4KB degradation. MG degrader 2 has anti-proliferative activity against MM.1S cells (IC₅₀ = 162 nM). MG degrader 2 can be used for the research of cancer, such as multiple myeloma .

HY-13312A

GTx-134	IGF-1R Insulin Receptor Akt Apoptosis	Cancer
GTx-134 is a dual insulin-like growth factor 1 receptor/insulin receptor (IGF-1R/IR) inhibitor with an IC₅₀ values for IGF-1R and IR of 97 and 187 nM respectively. GTx-134 inhibits the autophosphorylation of IGF-1R and its downstream signaling pathway (Akt), thereby blocking the proliferation and survival signals of tumor cells. GTx-134 has broad-spectrum inhibitory activity against multiple myeloma cell lines and can induce apoptosis in sensitive cells. GTx-134 significantly inhibits tumor growth in mice with MM1.S cell transplantation. GTx-134 works in synergy with existing therapies (such as protease preparations, immunomodulators). GTx-134 can be used in high-risk myeloma research .

HY-176207

HDAC degrader-1	ByeTAC HDAC	Cancer
HDAC6 degrader-6 (compound 10c) is a ByeTAC protein degrader targeting HDAC6, with IC₅₀ values of 0.034 μM, 0.166 μM, 0.703 μM, and 0.293 μM for HDAC6, HDAC1, HDAC2, and HDAC3, respectively. HDAC6 degrader-6 induces cell apoptosis and can be used for the study of multiple myeloma(Blue: USP14 ligand HY-159808; Pink: HDAC ligand HY-176209; Black: linker HY-W016871)

HY-102047A

KDOAM-25 trihydrochloride	Histone Demethylase	Cancer
KDOAM-25 trihydrochloride is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 trihydrochloride increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells .

HY-155671

HDAC6-IN-18	HDAC	Cancer
HDAC6-IN-18 (Compound 4) is a first irreversible HDAC6 isoform selective inhibitor with potent anti-multiple myeloma activity. HDAC6-IN-18 has HDAC6 inhibitory activity in RPMI8266, U266 and MM.1S cells with IC₅₀ values of 0.17, 0.7 and 0.42 μM, respectively .

HY-161250

Pomalidomide-NH-PEG6-amide-C2-CPI-1612	PROTACs	Cancer
Pomalidomide-NH-PEG6-amide-C2-CPI-1612 (compound 22 (dCE-1)) is a CBP/EP300 degrader, which contains a CRBN ligands Pomalidomide, a 24-atom linker with 6 PEG units and a HAT inhibitor CPI-1612. Pomalidomide-NH-PEG6-amide-C2-CPI-1612 exhibits antiproliferative effects in cells multiple myeloma cells LP1 (with a DC₅₀ of 1.2 μM), MM1S and various cancer cell lines, especially the leukemia cells .

HY-181023

PROTAC HDAC8 Degrader-3	PROTACs HDAC	Cancer
PROTAC HDAC8 Degrader-3 (Compound BP1) is an efficient and selective HDAC8 PROTAC degrader with a DC₅₀ of 20 nM. PROTAC HDAC8 Degrader-3 exhibits IC₅₀ for HDAC8 and CRBN of 0.46 and 7.5 μM, respectively. PROTAC HDAC8 Degrader-3 exhibits potent anti-proliferative activity against MM.1S and HL-60 cells. PROTAC HDAC8 Degrader-3 can be used for research on multiple myeloma and acute myeloid leukemia .

HY-105019AR

Melflufen hydrochloride (Standard) Melphalan flufenamide hydrochloride (Standard)	Reference Standards DNA Alkylator/Crosslinker Apoptosis	Cancer
Melflufen hydrochloride (Standard) is the analytical standard of Melflufen hydrochloride (HY-105019A). This product is intended for research and analytical applications. Melflufen (Melphalan flufenamide) hydrochloride, a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen hydrochloride shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen hydrochloride induces irreversible DNA damage and cytotoxicity in MM cells .

HY-182345

NOTA-MK0159	CD38	Cancer
NOTA-MK0159 is a NOTA (HY-134418) and MK0159 (HY-150508) conjugate. NOTA-MK0159 inhibits human and mouse CD38 with IC₅₀ values of 72.58 and 7.55 nM. NOTA-MK0159 coupled with radioactive elements acts as a imaging agent with specific uptake in CD38-positive multiple myeloma cells, enabling noninvasive whole-body assessment of CD38 expression in multiple myeloma xenografts. NOTA-MK0159 can be used for the research of multiple myeloma .

HY-123255

BSc2118	Proteasome MMP Apoptosis Autophagy	Cardiovascular Disease Neurological Disease Cancer
BSc2118 is a 20S proteasome inhibitor with an IC₅₀ of approximately 50 nM. BSc2118 induces G₂/M phase cell cycle arrest and apoptosis in myeloma cells, inhibits cytoprotective autophagy, and suppresses tumor angiogenesis. BSc2118 reduces MMP9 activity, promotes angioneurogenesis, and alleviates recombinant tissue-type plasminogen activator-induced cerebral toxicity. BSc2118 is applicable to studies related to cerebral ischemia and multiple myeloma .

HY-182801

PROTAC BRD4 Degrader-46	PROTACs Epigenetic Reader Domain c-Myc	Cancer
PROTAC BRD4 Degrader-46 is a heterobifunctional BRD4 PROTAC degrader. PROTAC BRD4 Degrader-46 binds to both BRD4 and CRBN, thereby triggering ubiquitination and proteasomal degradation of BRD4. PROTAC BRD4 Degrader-46 downregulates the levels of downstream BRD2, BRD3 and MYC. PROTAC BRD4 Degrader-46 can be used in the research of cancers such as multiple myeloma .

HY-123303

NSC-134754 NZ-28	HSP	Cancer
NSC-134754 (NZ-28) is a dehydroemetine derivative and heat shock protein (HSP) induction inhibitor. NSC-134754 acts at the post-transcriptional level, targets Hsp72 and Hsp27, and does not alter general protein synthesis, HSF-1 transcriptional activity, or Hsp mRNA levels. NSC-134754 can be used for the research of multiple myeloma, prostate carcinoma, colon carcinoma .

HY-183683

DQ-9	Proteasome Apoptosis	Cancer
DQ-9 is a selective immunoproteasome β5i inhibitor (IC₅₀=0.0019 μM). DQ-9 generates additional inhibitory substances via iron-mediated intracellular activation, and induces oxidative stress, carbon-centered free radicals and macromolecular damage through its artemisinin domain. DQ-9 induces apoptosis in leukemia and multiple myeloma cells. DQ-9 exhibits selective cytotoxicity against leukemia and multiple myeloma cells by elevating the labile iron pool. DQ-9 can be used in the research of hematological malignancies (leukemia, multiple myeloma, mantle cell lymphoma, acute myeloid leukemia) .

Cat. No.	Product Name	Target	Research Area

HY-105019

Melflufen 1 Publications Verification Melphalan flufenamide	DNA Alkylator/Crosslinker Apoptosis	Cancer
Melflufen (Melphalan flufenamide), a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen induces irreversible DNA damage and cytotoxicity in MM cells .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.